Nolan Garry Ph.D.'s Form 4 filing
Akoya Biosciences, Inc. (AKYA) · filed Dec 15, 2022
- Accession no.
- 0001104659-22-127461
- Filed
- Dec 15, 2022
- Trade date
- Dec 13, 2021
- Filing delay
- 367 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $1.32K. It was filed 367 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001104659-23-037255 (Mar 27, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nolan Garry Ph.D.CIK 0001857405 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | Common Stock | SSaleDisposed | −100 | $13.25 | −$1,325 | 555,084 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.